The FDA granted accelerated approval to selpercatinib for the treatment of certain pediatric patients with metastatic or advanced solid tumors harboring RET alterations.
The approval applies to children aged two years or older who require systemic therapy for advanced or metastatic medullary thyroid cancer with an RET mutation. The approval also applies to pediatric patients aged two years or older who require systemic therapy for radioactive iodine-refractory advanced or metastatic thyroid cancer with a RET gene fusion and those with locally advanced or metastatic solid tumors with a RET gene